River & Mercantile Asset Management LLP Purchases Shares of 3,311 Forty Seven Inc (NASDAQ:FTSV)

River & Mercantile Asset Management LLP purchased a new stake in Forty Seven Inc (NASDAQ:FTSV) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 3,311 shares of the company’s stock, valued at approximately $35,000.

A number of other large investors also recently made changes to their positions in the business. BlackRock Inc. grew its position in Forty Seven by 10.9% in the second quarter. BlackRock Inc. now owns 1,263,882 shares of the company’s stock valued at $13,399,000 after acquiring an additional 124,286 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Forty Seven by 2.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 709,796 shares of the company’s stock worth $7,524,000 after purchasing an additional 14,591 shares in the last quarter. Citadel Advisors LLC boosted its stake in Forty Seven by 8.5% in the second quarter. Citadel Advisors LLC now owns 510,309 shares of the company’s stock worth $5,409,000 after purchasing an additional 39,871 shares in the last quarter. Vanguard Group Inc. boosted its stake in Forty Seven by 1.2% in the second quarter. Vanguard Group Inc. now owns 499,451 shares of the company’s stock worth $5,294,000 after purchasing an additional 5,741 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Forty Seven by 48.4% in the second quarter. JPMorgan Chase & Co. now owns 379,731 shares of the company’s stock worth $3,953,000 after purchasing an additional 123,921 shares in the last quarter. Hedge funds and other institutional investors own 36.17% of the company’s stock.

In other Forty Seven news, major shareholder Lightspeed Venture Partners X, purchased 625,000 shares of the stock in a transaction on Monday, July 22nd. The stock was bought at an average cost of $8.00 per share, for a total transaction of $5,000,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Bird purchased 750,000 shares of the stock in a transaction on Monday, July 22nd. The stock was acquired at an average price of $8.00 per share, with a total value of $6,000,000.00. The disclosure for this purchase can be found here. 37.40% of the stock is owned by corporate insiders.

A number of research firms have commented on FTSV. ValuEngine raised Forty Seven from a “hold” rating to a “buy” rating in a research note on Friday, August 16th. HC Wainwright set a $21.00 price target on Forty Seven and gave the company a “buy” rating in a research note on Friday, July 12th. Oppenheimer cut their price target on Forty Seven from $35.00 to $20.00 in a research note on Wednesday, August 14th. Mizuho initiated coverage on Forty Seven in a research note on Wednesday, September 11th. They set a “buy” rating and a $18.00 price target on the stock. Finally, Zacks Investment Research raised Forty Seven from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a research note on Thursday, September 12th. Nine investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $23.14.

NASDAQ FTSV opened at $5.97 on Friday. The stock has a 50-day simple moving average of $7.05 and a 200 day simple moving average of $11.28. Forty Seven Inc has a 12 month low of $5.69 and a 12 month high of $23.83.

Forty Seven (NASDAQ:FTSV) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.05). On average, equities research analysts predict that Forty Seven Inc will post -2.13 EPS for the current year.

About Forty Seven

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Further Reading: Trading Stocks – What are percentage gainers?

Institutional Ownership by Quarter for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.